NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

Provided By PR Newswire

Last update: Sep 4, 2025

ZURICH, Sept. 4, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company") today announced that its merger partner Kadimastem Ltd. (TASE: KDST) ("Kadimastem") has been granted a patent by the Hong Kong Intellectual Property Department covering Kadimastem's proprietary cell selection and enrichment technology used in the development of IsletRx, a stem cell–derived therapy candidate intended to treat—and potentially cure—insulin-dependent diabetes.